Tyra Biosciences, Inc. Debt Securities, Available-for-sale, Unrealized Loss
Tyra Biosciences, Inc. (TYRA) reported Debt Securities, Available-for-sale, Unrealized Loss of $124.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2026-05-13
- Tyra Biosciences, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2026-03-31 was $124.00K, a 1027.27% increase year-over-year.
- Tyra Biosciences, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-12-31 was -$19.00K, a 173.08% decline year-over-year.
- Tyra Biosciences, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-09-30 was $3.00K.
- Tyra Biosciences, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-06-30 was $5.00K, a 97.22% decline year-over-year.
- Tyra Biosciences, Inc. debt securities, available-for-sale, unrealized loss for fiscal 2024 was $27.00K, a 800.00% increase from fiscal 2023.
- Tyra Biosciences, Inc. debt securities, available-for-sale, unrealized loss for fiscal 2023 was $3.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2026-03-31 | $124.00K 10-Q · filed 2026-05-13 | $105.00K derived: sum of 2 quarters · filed 2026-05-13 | $108.00K derived: sum of 3 quarters · filed 2026-05-13 | $113.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | -$19.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-05-13 | -$16.00K derived: sum of 2 quarters · filed 2026-05-13 | -$11.00K derived: sum of 3 quarters · filed 2026-05-13 | $0.00 10-Q · filed 2026-05-13 |
| 2025-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $8.00K derived: sum of 2 quarters · filed 2025-11-05 | $19.00K 10-Q · filed 2025-11-05 | $45.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $16.00K 10-Q · filed 2025-08-14 | $42.00K derived: sum of 3 quarters · filed 2026-03-02 | -$213.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-03-31 | $11.00K 10-Q · filed 2025-05-08 | $37.00K derived: sum of 2 quarters · filed 2026-03-02 | -$218.00K derived: sum of 3 quarters · filed 2026-03-02 | -$38.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$229.00K derived: sum of 2 quarters · filed 2026-03-02 | -$49.00K derived: sum of 3 quarters · filed 2026-03-02 | $27.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | -$255.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$75.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.00K 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $180.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $256.00K 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | $76.00K 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $3.00K 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |